Primary |
Metastases To Bone |
28.5% |
Product Used For Unknown Indication |
25.4% |
Prostate Cancer |
8.6% |
Breast Cancer |
6.8% |
Breast Cancer Metastatic |
6.7% |
Prophylaxis |
5.9% |
Prostate Cancer Metastatic |
5.7% |
Pain |
1.8% |
Bone Disorder |
1.6% |
Hypertension |
1.5% |
Lung Neoplasm Malignant |
1.4% |
Neoplasm Malignant |
1.2% |
Osteoporosis |
0.9% |
Chemotherapy |
0.7% |
Renal Cell Carcinoma |
0.7% |
Hypocalcaemia |
0.6% |
Lung Cancer Metastatic |
0.6% |
Supplementation Therapy |
0.5% |
Bone Giant Cell Tumour |
0.5% |
Hypothyroidism |
0.5% |
|
Hypocalcaemia |
23.6% |
Osteonecrosis Of Jaw |
22.4% |
Death |
14.0% |
Bone Pain |
4.6% |
Pain In Jaw |
3.8% |
Tooth Disorder |
3.8% |
Hypophosphataemia |
3.4% |
Dyspnoea |
2.7% |
Incorrect Route Of Drug Administration |
2.6% |
Rash |
2.6% |
Blood Calcium Decreased |
2.2% |
Neoplasm Malignant |
1.9% |
Pain |
1.9% |
Hypercalcaemia |
1.6% |
Vomiting |
1.6% |
Fatigue |
1.6% |
Toothache |
1.5% |
Hospitalisation |
1.4% |
Muscle Spasms |
1.4% |
Paraesthesia |
1.4% |
|
Secondary |
Metastases To Bone |
27.1% |
Product Used For Unknown Indication |
18.3% |
Prostate Cancer |
13.3% |
Breast Cancer Metastatic |
6.7% |
Breast Cancer |
6.3% |
Prostate Cancer Metastatic |
5.9% |
Pain |
4.3% |
Prophylaxis |
3.4% |
Osteoporosis |
2.3% |
Lung Neoplasm Malignant |
2.0% |
Lung Cancer Metastatic |
1.4% |
Hypertension |
1.2% |
Chemotherapy |
1.1% |
Nausea |
1.1% |
Osteoporosis Postmenopausal |
1.1% |
Fibrous Dysplasia Of Bone |
1.0% |
Hypercalcaemia |
1.0% |
Atrial Fibrillation |
0.9% |
Breast Cancer Recurrent |
0.9% |
Bone Disorder |
0.7% |
|
Osteonecrosis Of Jaw |
22.7% |
Hypocalcaemia |
13.6% |
Death |
7.4% |
Tremor |
5.7% |
Paraesthesia |
4.5% |
Spinal Fracture |
4.5% |
Bone Pain |
4.0% |
Dyspnoea |
4.0% |
Muscle Spasms |
4.0% |
Pain |
4.0% |
Fall |
3.4% |
Pain In Jaw |
3.4% |
Fatigue |
2.8% |
Rash |
2.8% |
Tooth Disorder |
2.8% |
Prothrombin Time Ratio Increased |
2.3% |
Swelling |
2.3% |
Toothache |
2.3% |
Arthralgia |
1.7% |
Groin Pain |
1.7% |
|
Concomitant |
Product Used For Unknown Indication |
50.6% |
Prostate Cancer |
11.2% |
Breast Cancer Metastatic |
5.2% |
Prostate Cancer Metastatic |
4.3% |
Breast Cancer |
3.9% |
Metastases To Bone |
3.4% |
Pain |
3.3% |
Prophylaxis |
2.9% |
Nausea |
2.9% |
Hypertension |
2.3% |
Supplementation Therapy |
2.1% |
Constipation |
1.0% |
Anxiety |
1.0% |
Bone Disorder |
0.9% |
Depression |
0.9% |
Non-small Cell Lung Cancer |
0.9% |
Gastrooesophageal Reflux Disease |
0.8% |
Lung Neoplasm Malignant |
0.8% |
Diabetes Mellitus |
0.8% |
Chronic Obstructive Pulmonary Disease |
0.7% |
|
Weight Decreased |
13.7% |
Vomiting |
8.4% |
Death |
7.6% |
Prostatic Specific Antigen Increased |
7.6% |
Disease Progression |
6.1% |
Nausea |
6.1% |
Diarrhoea |
5.3% |
Respiratory Failure |
5.3% |
Prostate Cancer |
3.8% |
Stomatitis |
3.8% |
Thrombocytopenia |
3.8% |
Vision Blurred |
3.8% |
Malignant Neoplasm Progression |
3.1% |
Pain |
3.1% |
Pain In Extremity |
3.1% |
Pneumonia |
3.1% |
Pyrexia |
3.1% |
Urticaria |
3.1% |
Weight Increased |
3.1% |
White Blood Cell Count Decreased |
3.1% |
|